HALO Gears Up to Report Q4 Earnings: Here's What You Should Know

Core Viewpoint - Halozyme Therapeutics (HALO) is set to report its fourth-quarter and full-year 2024 results on February 18, with revenue expectations of $284.3 million and earnings of$1.16 per share [1]. Group 1: Financial Performance - In the past year, Halozyme's shares have increased by 65.8%, contrasting with a 3.5% decline in the industry [2]. - The company's revenue for the upcoming quarter is expected to be driven by higher royalty payments from Roche for Phesgo and from J&J for subcutaneous Darzalex due to strong demand [5]. - Revenue from collaborative agreements saw significant growth in the third quarter, a trend likely to continue into the fourth quarter [6]. Group 2: Product and Technology Impact - Halozyme's Enhanze technology is utilized by several companies to develop subcutaneous formulations of their marketed drugs, including J&J's Darzalex and Roche's Phesgo [4]. - The company has two proprietary products, Hylenex and Xyosted, with incremental sales from these products expected to contribute positively to revenues [6]. Group 3: Future Guidance - Due to strong business performance in 2024, Halozyme raised its 2025 revenue guidance to a range of $1.15 billion to$1.22 billion, indicating a year-over-year growth of 16% to 23% [9]. - Royalty revenues for 2025 are now anticipated to be between $725 million and$750 million, reflecting a year-over-year growth of 30% to 35% [9]. Group 4: Earnings Surprise History - Halozyme has a mixed earnings surprise history, beating earnings in three of the last four quarters and delivering an average surprise of 14.86% [11]. - In the last reported quarter, Halozyme achieved an earnings surprise of 28.28% [11].